Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial

Aditya H. Gaur(St. Jude Children's Research Hospital), R. Kiplin Guy(St. Jude Children's Research Hospital), John Woodford(National Institute of Allergy and Infectious Diseases), Amber M. Smith(University of Tennessee Health Science Center), Nehali Patel(St. Jude Children's Research Hospital), Ronald H. Dallas(St. Jude Children's Research Hospital), John C. Panetta(St. Jude Children's Research Hospital), Tracy B. Stewart, Ryan N. Heine(St. Jude Children's Research Hospital), Burgess B. Freeman(St. Jude Children's Research Hospital), James McCarthy(Walter and Eliza Hall Institute of Medical Research), Lidiya Bebrevska(Medicines for Malaria Venture), Kristen Branum(St. Jude Children's Research Hospital), Yvonne Van Gessel(Eisai (United States)), Shelley Ost(University of Tennessee Health Science Center), Branko Mitasev(Eisai (United States)), Li Tang(St. Jude Children's Research Hospital), Robbin Christensen(St. Jude Children's Research Hospital), Fabian Gusovsky(Eisai (Japan)), Julie Richardson(St. Jude Children's Research Hospital), Elizabeth John, Patricia M. Flynn(St. Jude Children's Research Hospital), Jörg J. Möhrle(Medicines for Malaria Venture), Stephan Chalon(Medicines for Malaria Venture)
The Lancet Infectious Diseases
April 7, 2020
Cited by 77


Related Papers